Copyright 2018 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +25.32% per year. These returns cover a period from January 1, 1988 through November 5, 2018. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations.
Visit performance for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
pharmaceuticals: Archive
3 Sector ETFs to Bet On Despite Soft November Jobs Data
by Sanghamitra Saha
These sector ETFs should gain post November jobs data.
FXH IYT XME FTXR
basic-materials medical pharmaceuticals transportation
Roche's Tecentriq Gets FDA Approval for First-Line NSCLC
by Zacks Equity Research
Roche's (RHHBY) Tecentriq in combination with Avastin obtains FDA nod for the initial treatment of NSCLC.
RHHBY BMY MRK GILD
pharmaceuticals
5 Top Drug/Biotech Merger & Acquisition Targets for 2019
by Kinjel Shah
Here are five stocks that are attractive and most likely to be takeout targets in 2019.
SNY ALXN CELG INCY BMRN VRTX ALNY
pharmaceuticals
Mallinckrodt (MNK) to Separate Generics & Branded Businesses
by Zacks Equity Research
Mallinckrodt (MNK) announces plans to split its generic and branded businesses into two different companies.
LLY BMY MRK MNK
pharmaceuticals
Novartis Presents Additional Data on Breast Cancer Candidate
by Zacks Equity Research
Novartis (NVS) presents supplementary data from phase III study on BYL719 in combination with Faslodex for the treatment of advanced breast cancer. The study scripts success in PFS.
MRK NVS AZN BMY
pharmaceuticals
AstraZeneca's Imfinzi Fails in Head and Neck Cancer Study
by Zacks Equity Research
AstraZeneca's (AZN) Imfinzi monotherapy and combination therapy fail to meet overall survival endpoint in phase III EAGLE study.
BMY AZN MRK INCY
pharmaceuticals
Pharma Stock Roundup: Glaxo's TESARO Buyout & Horlicks Sale, ASH Cancer Data Updates
by Zacks Equity Research
Glaxo (GSK) to buy TESARO and divest Horlicks brand to Unilever. ASH cancer presentations grab headilines.
PFE ABBV GSK JNJ NVS AZN RHHBY
pharmaceuticals
Roche's Kadcyla Halves Death Risk in Breast Cancer Study
by Zacks Equity Research
Roche (RHHBY) announces detailed data from a late-stage study on Kadcyla in early breast cancer patients. Kadcyla reduces risk of disease recurrence by 50% compared to Herceptin.
RHHBY NVS IMGN TEVA
pharmaceuticals
AbbVie Halts Rova-T Phase III Second-Line Lung Cancer Study
by Zacks Equity Research
IDMC recommends AbbVie (ABBV) to stop enrolment in a late-stage study on its small cell lung cancer candidate, Rova-T.
ABBV MRK JNJ RHHBY
pharmaceuticals
Shire (SHPG), Takeda Shareholders Approve $62 Billion Merger
by Zacks Equity Research
Shire's (SHPG) pending acquisition by Takeda Pharmaceuticals for $62 billion gets approval from shareholders of both the companies.
AGN INCY BMRN SHPG
pharmaceuticals
Mixed Trade War Signals, the Moonves Scandal, & CVS' Drug Price Plan
by Ryan McQueeney
Ryan McQueeney discusses the latest drama in the U.S.-China trade war, new developments in Les Moonves' departure from CBS, and a new drug pricing plan from pharmacy giant CVS.
CBS CVS
insurance pharmaceuticals retail
J&J's Blood Cancer Drugs Succeed in Label Expansion Studies
by Zacks Equity Research
J&J (JNJ) presents positive data from late-stage studies evaluating its blood cancer drugs, Imbruvica and Darzalex, in the first-line setting at ASH.
ABBV JNJ RHHBY CELG
pharmaceuticals
Mylan Expands Recall of Valsartan to All Unexpired Lots
by Zacks Equity Research
Mylan (MYL) expands recall of batches of blood pressure medicine in the United States to include all Valsartan-based products within expiry.
JNJ MRK TEVA MYL
pharmaceuticals
The Zacks Analyst Blog Highlights: Verizon, Eli Lilly, Accenture, VMware and Schwab
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Verizon, Eli Lilly, Accenture, VMware and Schwab
LLY VZ VMW SCHW ACN
business-services pharmaceuticals tech-stocks
Roche's Tecentriq Combination Gets Priority Review by FDA
by Zacks Equity Research
The FDA accepts and grants Priority Review to Roche's (RHHBY) sBLA for Tecentriq in combination with carboplatin and etoposide for the initial treatment of patients withextensive-stage small cell lung cancer.
RHHBY NVS BMY AMGN
pharmaceuticals
J&J Strikes Deal with argenx to Co-Develop Cancer Antibody
by Zacks Equity Research
Johnson & Johnson (JNJ) inks a global deal with Europe's argenx to jointly develop and globally commercialize the latter's prospective antibody, cusatuzumab.
JNJ BMY CELG ARWR
pharmaceuticals
Roche Announces Positive Data on Venclexta/Venclyxto at ASH
by Zacks Equity Research
Roche (RHHBY) announces new Venclexta/Venclyxto data that demonstrate deep responses in two of the most common types of leukaemia.
BMY RHHBY ABBV TEVA
pharmaceuticals
Company News For Dec 4, 2018
by Zacks Equity Research
Companies In The News Are: TSRO,GSK,TRCO,NXST,VNDA,GBT
GSK NXST TRCO GBT VNDA TSRO
consumer-discretionary medical pharmaceuticals
5 Top Dividend Aristocrats to Buy in December
by Tirthankar Chakraborty
With things not looking up for the stock market this December, it's prudent to invest in dividend aristocrats for their risk-adjusted returns.
APD MKC WBA VFC ADP
pharmaceuticals retail
FDA Accepts BLA & Gives Priority Review to Novartis' AVXS-101
by Zacks Equity Research
The FDA accepts Novartis' (NVS) BLA for AVXS-101 and grants Priority Review to the same.
NVS BIIB AXON QURE
pharmaceuticals
Glaxo to Buy Zejula Maker TESARO for $5.1B, Stock Down 8%
by Zacks Equity Research
Glaxo (GSK) announces definitive deal to buy TESARO.
AZN GSK CLVS TSRO
pharmaceuticals
Glaxo to Sell India's Popular Horlicks Brand to Unilever
by Zacks Equity Research
Glaxo (GSK) divests its Horlicks and other nutrition products in India to Unilever.
NVS GSK KO UL
pharmaceuticals
New Strong Buy Stocks for December 4th
by Tirthankar Chakraborty
Here are 5 stocks added to the Zacks Rank #1 (Strong Buy) List for Tuesday
TECD IIIV HCHC CASY BHC
pharmaceuticals
AbbVie Settles With Pfizer for Humira Biosimilar in U.S.
by Zacks Equity Research
AbbVie (ABBV) strikes a deal with Pfizer to launch its biosimilar of Humira in the United States in November
ABBV PFE AMGN MYL
pharmaceuticals
Shire's Takhzyro Gets European Nod for Hereditary Angioedema
by Zacks Equity Research
Shire's (SHPG) gets European approval for Takhzyro subcutaneous injection, for routine prevention of recurrent attacks of hereditary angioedema (HAE) in patients aged 12 years and older.
MRK BMY GILD SHPG
pharmaceuticals